-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Novarro's leukocyte mesotrogen-17A (IL-17A) monoantigenic Cosentyx (secukinumab) has been approved by the European Commission and can be used in the treatment of children and adolescents aged 6-18 with moderate to severe plaque psoriasis.
: The approval is based on two phase 3 studies of children and adolescents aged 6-18.
two studies, low-dose (75-150 mg) and high-dose (75-300 mg) Cosentyx quickly improved skin symptoms and quality of life.
low dose of Cosentyx can quickly remove skin, with 93% of children reaching the Psoriasis Regional Severity Index (PASI) 75 at week 12, 69% reaching PASI 90 in week 12 and 88% at week 24.
, 59.5 per cent of children received completely transparent skin (PASI 100) at week 12 and 67 per cent at week 24.
In patients with severe psoriasis, low doses of Consentyx helped maintain skin cleansing up to 52 weeks, with 75 percent achieving PASI 90 and 44.7 percent of patients achieving complete remission by 12 weeks.
.